# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Triapin 5 mg/5 mg, prolonged release tablets

#### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains 5 mg of felodipine and 5 mg of ramipril. Each tablet contains 51.5 mg lactose anhydrous. Each tablet also contains hydrogenated castor oil. For the full list of excipients, see section 6.1

## **3 PHARMACEUTICAL FORM**

Prolonged release tablet

Product imported from the Italy.

Triapin 5mg/5mg prolonged release tablets are reddish-brown and have "H/OE" marked on one side and "5" on the other side.

#### **4 CLINICAL PARTICULARS**

As per PA0540/082/002

## **5 PHARMACOLOGICAL PROPERTIES**

As per PA0540/082/002

#### **6 PHARMACEUTICAL PARTICULARS**

#### 6.1 List of excipients

Cellulose microcrystalline

Hyprolose

Hypromellose

Iron oxides (E172)

Lactose anhydrous

Macrogol 6000

Hydrogenated castor oil

Maize starch

Paraffin

Propyl gallate

Sodium aluminium silicate

Sodium stearyl fumarate

Titanium dioxide E171

## 6.2 Incompatibilities

Not applicable

#### 6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the blister and outer carton of the product as marketed in the country of origin.

#### 6.4 Special precautions for storage

Do not store above 25°C

27 January 2023 CRN00C2VQ Page 1 of 2

## **6.5 Nature and contents of container**

Blisters 28 tablets

# 6.6 Special precautions for disposal

No special requirements

## **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

Merit Pharmaceuticals Limited Unit C4/C3 Metropoint Business Park Kettles Lane Swords Co Dublin K67 RH92 Ireland

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA23080/015/001

# 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 11<sup>th</sup> March 2016

#### 10 DATE OF REVISION OF THE TEXT

January 2023

27 January 2023 CRN00C2VQ Page 2 of 2